• John H Lee, Joseph R Linzey, Michael J Strong, Varun G Kathawate, Peyton E Goethe, Lila R Tudrick, Arushi Tripathy, Sravanthi Koduri, Paul Gagnet, Ayobami L Ward, Oludotun Ogunsola, Mark M Zaki, Rushikesh S Joshi, Joseph Evans, William C Jackson, and Nicholas J Szerlip.
• School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
• World Neurosurg. 2023 Oct 1; 178: e403e409e403-e409.

BackgroundThe outcomes for patients with metastatic renal cell carcinoma (RCC) to the spine who underwent stereotactic body radiotherapy (SBRT) through a multidisciplinary spine oncology program are not well described. We sought to describe the clinical course and local control rates at 1 and 2 years for these patients.MethodsA retrospective analysis of a prospectively maintained database of adult oncologic patients receiving SBRT to the spine through a multidisciplinary spine oncology program at a single institution from 2010 to 2021 was performed. Patients with a pathologic diagnosis of RCC were included.ResultsA total of 75 spinal sites were treated in 60 patients. Of the 60 patients, 75.0% were men, and the mean patient age was 59.2 ± 11.3 years. At 1 year after treatment, 6 of the 60 patients were lost to follow-up. Of the remaining 54 patients, 18 were censored by death and 7 treatment sites showed local recurrence, for 37 of 44 treatment sites with local control (87.8%). At 2 years, 1 additional local recurrence had developed, 15 patients were censored by death, and no additional patients had been lost to follow-up, resulting in 28 of 36 treatment sites with local control (83.2%). None of the patients who had undergone repeat SBRT had local recurrence at 1 or 2 years. For those with local recurrence, the average time from treatment to progression was 6.6 ± 6.5 months.ConclusionsIn this cohort, one of the largest reported studies of spine SBRT for metastatic RCC, local control was high at 1 and 2 years. Our findings support the role of coordinated, algorithmic treatment for these patients.Copyright © 2023 Elsevier Inc. All rights reserved.

6 keywords...

hide…